News
StockStory.org on MSN16h
MRNA Q1 Earnings Call: Management Focuses on Cost Reductions and Pipeline Progress Amid Revenue ShortfallBiotechnology company Moderna (NASDAQ:MRNA) in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The ...
Learn more about whether Kymera Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades ...
More than 3,000 GPTs are reportedly in use at Moderna, which has partnered with OpenAI. Here's how they're using the technology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results